Construction firm Ebenbuild secures funding from Entrepreneurship and Innovation Collection
Ebenbuild's Twinhale: Revolutionizing Respiratory Medicine with AI-Powered Decision Support
Ebenbuild, a healthtech company focused on respiratory diseases, is set to launch its flagship product, Twinhale, following a €2.3 million grant from the European Innovation Council (EIC) Accelerator program. This investment will accelerate the rollout of Twinhale, aiming to revolutionize the field of respiratory medicine [1][2].
Twinhale, a digital twin platform technology, digitally simulates medication administration via the lungs. In a validation study, the software accurately predicted local drug deposition, outperforming existing models and enabling design decisions that would not have been possible with in-vivo or in-vitro tests [1].
The target customers for Twinhale are pharmaceutical and medical technology companies. By reducing failure rates in the development of respiratory medications and generating unique datasets for regulatory approval and companion diagnostic strategies, Twinhale is poised to make a significant impact in the industry [1].
Ebenbuild's long-term goal is to enter the markets for clinical decision support systems (CDSS) and personalized medicine. Given the growing demands for AI-enhanced diagnostics and personalized treatment strategies, Twinhale seems well-positioned to address these needs [1][2]. The market potential for CDSS and personalized medicine is estimated to reach over €300 billion by 2030 [1].
The current EIC funding is considered non-dilutive capital, meaning it does not dilute the ownership of existing shareholders. This funding will support the development and scaling of Ebenbuild's digital twin platform technology, with a focus on the Twinhale software [1].
Ebenbuild is already active on the global €5 billion-plus market for in-silico studies. The company's vision is to become the leading health information platform for respiratory diseases, and it is supported by HTGF, Bayern Kapital, and several angel investors [1].
In addition, the EIC Fund has earmarked up to €10 million for future equity financing for Ebenbuild [1]. Dr. Maximilian Grill, Head of In-silico Studies at Ebenbuild, highlighted the potential of Twinhale, stating that it reduces failure rates in the development of respiratory medications and generates unique datasets for regulatory approval and companion diagnostic strategies [1].
As Ebenbuild moves towards the market launch of Twinhale, the company is poised to make a significant impact in the field of respiratory medicine. With its advanced AI technologies and focus on personalized medicine, Ebenbuild is at the forefront of the growing trend towards digitalization in healthcare [1][2].
[1] [Source 1] [2] [Source 2]
Start-ups in the healthtech sector, such as Ebenbuild, are leveraging science and technology to revolutionize medical-conditions management, as demonstrated by their AI-powered decision support system, Twinhale, in the field of respiratory medicine. This innovative software, if successfully implemented, could potentially be applied in clinical decision support systems (CDSS) and personalized medicine, aligning with the growingfinance-backed demands for AI-enhanced healthcare in the business world. The financial backing from the European Innovation Council (EIC) Accelerator program will enable Ebenbuild to scale its technology and penetrate the over €300 billion market for CDSS and personalized medicine by 2030.
